Sun, Apr 20, 2014, 12:09 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Dendreon Corp. Message Board

  • sol_s_99 sol_s_99 Feb 25, 2003 12:51 PM Flag

    Deal won't happen as is...

    CVAS shareholders will vote down deal at these prices. 84% premium to a 30% premium in one day ain't gonna make it. Especially because it's for stock. There has to be some sort of guaranteed premium for this to fly.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • You could be right. Apparently the number of DNDN shares in the deal is fixed, so CVAS shareholders aren't getting $73 million anymore, at least as of the moment.
      Another point for DNDN is that the CVAS primary trial(rNAPc2) is apparently paid for in advance. This suggests that the CVAS cash could go primarily toward the Provenge PC program.

    • ivesting in yet to be fda approved drugs is a big gamble, that said the dec. 11 press release in my veiw talks of significatant
      p-value of 0.002 and a treatment effect of 78%
      ...and after 6 months the randomization had a greater than 8-fold advantagle in progression
      -free survival ---34.7% verse 4 % of placebo.
      I think for dead men walking there is clear
      benifit here, as there is no therapy for this group. patients with gleason scale above 8 did not benefit

    • Now DNDN is in 2 major therapuetic areas that are both expensive to move in and develop. This is not good IMO.

      Also, much depends on Provenge, and some/many believe the data so far are not so great. If Provenge were to fail, CVAS shareholders would no doubt begin the shareholder suit parade. All-in-all, if this is simply a way for DNDN to get cash, IMHO they should have raised it on the strength of Provenge. If they have been unable to do that, a "short-cut" like this may mean that internal confidence in Provenge may not be as great as many hope or believe.

    • <<But apparently they don't intend to fund the continuation of that trial with DNDN/CVAS funds. Also would not surprise me to see some reduction in overhead due to duplication. >>

      I agree. Once the merger is done, they can cut spending on CVAS programs.

    • ivesting in yet to be fda approved drugs is a big gamble, that said the dec. 11 press release in my veiw talks of significatant
      p-value of 0.002 and a treatment effect of 78%
      ...and after 6 months the randomization had a greater than 8-fold advantagle in progression
      -free survival ---34.7% verse 4 % of placebo.
      I think for dead men walking there is clear
      benifit here, as there is no therapy for this group. patients with gleason scale above 8 did not benifit

    • my info tells me a few hedge funds are selling all they can of dndn to keep it down.. probably up to close to one million shares short now.. this shows you what pricks shorts are in general betting against a cure for cancer for men..the devil loves those types.. they would kill their mother for a buck...thats o.k. because i know more than they know about the science.. their happened to be a generic company i owned once that was bought out at 19.. I started buying at two bucks....time is on my side...

    • << if i follow your thinking, cvas just gave dndn 100 million bucks for a pile of worthless stock>>>

      Not quite by a factor of 2. Current(2/03) cash and equivalent at CVAS is about $63 million, and debt is $14 million, leaving just under $50 million cash. CVAS is also burning cash at close to $2 million per month.

    • I checked the CVAS message board, apparentlly, prior to the deal there was not much faith in the phase II trial, but it had already been funded. With DNDN in control they will do what ever is necessary, including both companies R&D,the need for mutiple facilities, overlapping functions, etc. This was a smart move by both companies. DNDN is now stronger than ever. It has cash and a diversified pipeline addressing major markets. I can see oppotunities to out-license programs that neither company could do before the merger.
      The CVAS programs or the DNDN programs will have to be evaluated. The result will be additional cash.

    • I think that the market sees this for what it is--a grab for cash.

      This is not the first transaction like this in biotech and it will not be the last. There is an assumption that Provenge is partnerable, where is the hard core data to support that? It does not exist. The trials have to be done and those trials are expensive. Everyone seems to suggest that JNJ is interested. Why would they pay up now when they can get it later and when they can see the final data? Sure they might pay a little more later, but the big pay days for biotech drugs, ala IMCL are long over. All of the money they just inherited will go to pushing Provenge forward. Will it be worth it? You will have to wait and see, but if this thing goes through you will have to deal with the downward pressure on the stock as CVAS holders rotate out. Mitch Gold is placing a very big bet.

    • you are wrong- read the remmision rate on the feb 23 release

    • View More Messages
 
DNDN
2.65-0.04(-1.49%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
AsiaInfo-Linkage, Inc.
NasdaqGSWed, Jan 15, 2014 4:00 PM EST